Christian-Albrechts-Universitat Zu Kiel

Dritte Patentportfolio Beteiligungsgesellschaft Mbh &Co. Kg

Christian-Albrechts-Universitaet Zu Kiel

Develco Pharma Schweiz Ag

Dennis Schade

Bernd Clement

Jürke Kotthaus

Joscha Kotthaus

Juerke Kotthaus

The invention relates to oseltamivir derivatives as influenza neuraminidase inhibitors for treating influenza infections and to a method for producing said compounds.

Compounds for the treatment of influenza

The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria.

Orally bioavailable pentamidine prodrugs for the treatment of diseases

The present invention relates to physically-chemically and pharmacokinetically enhanced N-hydroxy-L-arginine (NOHA) derivatives and a method for producing the NOHA derivatives having enhanced physical-chemical and pharmacokinetic properties according to the invention.

[object Object]

The invention relates to an inhibitor of dimethylarginine dimethylaminohydrolase (DDAH) of general structural formula (I), wherein B is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of 3 to 6; Ris selected from the group of structures (i-vii), wherein R, Rand Rare selected from the group consisting of hydrogen, an alkyl or aryl radical, Rand Rare selected from the group consisting of hydrogen, a hydrocarbon chain having a chain length of 1 to 8 and an aryl radical, R, R, Rand Rare selected from the group consisting of hydrogen, and alkyl or aryl radical; W is oxygen (O) or nitrogen (N); and X is a methylene group (CH) or a secondary amino group (NH); Y is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of 3 to 6; Z is hydrogen (H) or a methoxyl group; and the radical (B) carrying the amino group has no carboxyl group.

Inhibitors of dimethylarginine dimethylaminohydrolase

The present invention relates to prodrug derivatives of dabigatran, their use in the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis.

Growing community of inventors

La Jolla, CA, United States of America

Dennis Schade